Lisa Domegan
A5009951708- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- COVID-19 and healthcare impacts
- Pneumonia and Respiratory Infections
- Climate Change and Health Impacts
- Data-Driven Disease Surveillance
- Syphilis Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- Respiratory Support and Mechanisms
- Global Health Care Issues
- Viral Infections and Vectors
- Health disparities and outcomes
- HIV, TB, and STIs Epidemiology
- Sepsis Diagnosis and Treatment
- Animal Virus Infections Studies
- Animal Disease Management and Epidemiology
- Viral Infections and Outbreaks Research
- Virus-based gene therapy research
- Antibiotic Resistance in Bacteria
- HIV, Drug Use, Sexual Risk
- Infectious Encephalopathies and Encephalitis
Health Protection Surveillance Centre
2016-2025
Health Service Executive
2010-2024
European Centre for Disease Prevention and Control
2019-2023
Hospital Clínico Universitario de Valladolid
2017
Trinity College Dublin
2002
Residents in long-term care facilities (LTCF) are a vulnerable population group. Coronavirus disease (COVID-19)-related deaths LTCF residents represent 30-60% of all COVID-19 many European countries. This situation demands that countries implement local and national testing, infection prevention control, monitoring programmes for order to identify clusters early, decrease the spread within between reduce size severity outbreaks.
A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause for 24 European countries/federal states participating monitoring public health action (EuroMOMO) network, period March–April 2020. Excess particularly affected ≥ 65 year olds (91% all deaths), but also 45–64 (8%) and 15–44 (1%). No was observed 0–14 olds.
Since the 2008/9 influenza season, I-MOVE multicentre case–control study measures vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE A(H3N2) within season. Using combined data from 2010/11 to 2014/15 we studied effects of time since vaccination on type/subtype-specific VE. We modelled by using restricted cubic spline, controlling for potential confounders (age, sex, onset,...
Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high mortality during influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe and influenza-attributable season in Europe.Based on weekly reporting from 24 countries or sub-national regions, representing 60% population excluding Russian Turkish parts Europe, we estimated age stratified morality using model. In addition, was FluMOMO algorithm, incorporating activity...
Since December 2016, excess all-cause mortality was observed in many European countries, especially among people aged ≥ 65 years. We estimated and influenza-attributable 19 countries/regions. Excess primarily explained by circulation of influenza virus A(H3N2). Cold weather snaps contributed some countries. The pattern similar to the last major A(H3N2) season 2014/15 Europe, although starting earlier line with early start.
Although influenza-like illnesses (ILI) and acute respiratory (ARI) surveillance are well established in Europe, the comparability of intensity among countries seasons remains an unresolved challenge. The objective is to compare ILI ARI some European countries.Weekly incidence rates proportion primary care consultations were modeled 28 for 1996/1997-2013/2014 using moving epidemic method (MEM). We calculated threshold three thresholds, which delimit five levels: baseline, low, medium, high,...
The European monitoring of excess mortality for public health action (EuroMOMO) network monitors weekly all-cause in 27 countries or subnational areas. During the first wave coronavirus disease (COVID-19) pandemic Europe spring 2020, several experienced extraordinarily high levels mortality. is currently seeing another upsurge COVID-19 cases, and EuroMOMO again witnessing a substantial attributable to COVID-19.
Abstract Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test‐negative study. Materials Methods Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since...
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 season Europe. Among 5547 SARI ≥18 years, 2963 (53%) were vaccinated influenza. Overall VE A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% -4-39) A(H3N2) and 56% 22-75) B. During season, while hospitalisation B >55%, it ≤20% for A subtypes. While vaccination should be...
Binary file ES_Abstracts_Final_ECDC.txt matches
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. included 592 cases and 4,372 controls the main analysis. The VE was 62% (95% CI: 45–74) for one dose only 89% 79–94) complete vaccination. vaccines provide good protection presentation level, particularly fully vaccinated individuals.
Abstract Background In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure vaccine effectiveness (VE). Methods Primary practitioners collected information on patients presenting with acute respiratory infection. Cases were A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls virus negative. We calculated VE using logistic regression, adjusting for site, age, sex, onset date, presence of chronic...
Background Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim We aimed to estimate primary series (PS) and first booster VE symptomatic BA.1/BA.2 infection investigate potential biases. Methods This test-negative multicentre study tested care patients with acute respiratory symptoms for the BA.1/BA.2-dominant period. estimated PS among adults adolescents (PS only) all products combined Comirnaty alone,...
Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 VE age genetic subgroups to explore cohort. Methods We measured against (sub)clades. stratified usual groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of (I-REV) hypothesis,...
In October 2020 SARS-CoV-2 seroprevalence among hospital healthcare workers (HCW) of two Irish hospitals was 15 and 4. 1%, respectively. We compare in the same HCW population 6 months later, assess changes risk factors for seropositivity with progression pandemic serological response to vaccination.
Since the end of November 2023, European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate 95.3 (95% CI: 91.7–98.9) all-cause deaths per 100,000 person-years for all ages. This is seen adults aged 45 years and older, coincides with widespread presence COVID-19, influenza respiratory syncytial virus (RSV) many countries during 2023/24 winter season.
Abstract Hospital healthcare workers (HCWs) are at increased risk of contracting COVID-19 infection. We aimed to determine the seroprevalence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in HCWs Ireland. Two tertiary referral hospitals Irish cities with diverging community incidence and were identified; had been diagnosed 10.2% 1.8% staff respectively by time study (October 2020). All both ( N = 9038) invited participate an online questionnaire blood sampling for...
Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with or acute respiratory symptoms at primary care/community level 10 European countries were tested for SARS-CoV-2. We complete course overall VE by brand time since vaccination. Results Overall was 74% (95% CI: 69–79), 76% 71–80), 63% 48–75) 16–83) among those...
Introduction The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim We aimed to measure VE against PCR-confirmed SARS-CoV-2 patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 July 2022 (Omicron-dominant period). Methods In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. defined complete...
Abstract Background Healthcare workers (HCWs) are at increased risk of SARS-CoV-2 infection. This persists despite the implementation mitigating factors, including vaccination. The ongoing impact incident infection and symptomatic COVID-19 disease in vaccinated HCWs is poorly understood. Aim We aimed to describe epidemiology infections, as well investigating serological, clinical demographic factors associated with developing Design was a multi-centre prospective longitudinal study followed...
Expansion of the current single hospital site Severe Acute Respiratory Infection (SARI) surveillance programme in Ireland, to create a SARI sentinel network, commenced 2023. This evaluation aimed assess performance key system attributes improve and guide expansion. A mixed quantitative qualitative was conducted from September 2021 November 2022 using European Centre for Disease Prevention Control (ECDC) guidance as framework. data were analysed completeness timeliness. Semi-structured focus...
Human respiratory syncytial virus (HRSV) is a common cause of lower tract infections globally, and changes in viral epidemiology have been observed many jurisdictions following the coronavirus disease 2019 (COVID-19) pandemic. Newly licensed vaccines monoclonal antibodies are anticipated to alleviate burden on healthcare systems, though such interventions may exert selective pressures evolution. To evaluate diversity HRSV Ireland pre- post-COVID-19 pandemic, whole-genome sequencing was...